Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Bucknelly21on Aug 19, 2022 3:37pm
136 Views
Post# 34908241

RE:RE:Sortilin 1 Promotes Hepatocellular Carcinoma

RE:RE:Sortilin 1 Promotes Hepatocellular Carcinoma

I think thats a really good question that hasnt been discussed, I also would be really curious to know that if you basically reverse the tumor does that mean it stops expressing sortilin because isn't 1902 clogging the receptor?


Wino115 wrote: This is a July 2022 article from a lab in China. I guess they're essentially showing what others have presented on the correlation between high sortilin expression and survivability --the worse the cancer, the higher the sortilin expression and the lower your probability of survival.  So far, THTX has not mentioned liver cancer as one in the basket trial and I don't recall it being one in the original KOL presentation material from a few years ago mentioned as a high sort1 target to go after. 

As I was looking through the charts on this, it did bring up a question in my mind that maybe the more science-oriented posters can offer a thought or two on.  And that is, if TH1902 works due to the overexpression of sort1 typically seen in late stage solid tumor cancers, as it works to lower the tumor burden and cancer spread, does this reversion also lower the expression?  In other words, if I take a stage 4/5 cancer and effectively reverse it back down to a stage 2/1 or less, won't that effect the efficacy of TH1902 going forward?

I suppose that's the problem with many cancer drugs and perhaps why there can still be  many side effects as they improve.  But for one that whose target is correlated with the severity of the disease, I guess there's a tipping point in which it's effectiveness is lessened.  The pre-clinical didn't show that and maybe it's all about getting as much in the tumor to do it's thing as you can in the early stage and then  you can modulate it lower if you need to.  Anyway, a question for the scientists.






https://pubmed.ncbi.nlm.nih.gov/35847356/




 

Joemare wrote: Sortilin 1 Promotes Hepatocellular Carcinoma Cell Proliferation and Migration by Regulating Immune Cell Infiltration


2022 Jul 8;2022:6509028.
 doi: 10.1155/2022/650902




<< Previous
Bullboard Posts
Next >>